Prebiotics for depression: how does the gut microbiota play a role?

Area of Science:

• Nutritional Neuroscience
• Microbiome Research
• Psychiatry

Background:

• Depression is a significant mood disorder impacting daily life.
• Prebiotics, beneficial for gut microbiota, are explored for mental health benefits.
• Various prebiotics, including GOS, EGCG, and n-3 fatty acids, are investigated for antidepressant potential.

Purpose of the Study:

• To review clinical trials on carbohydrate-type prebiotics, phytochemicals, and lipids for depression.
• To assess the efficacy of specific prebiotics in mitigating depressive symptoms.
• To explore the mechanisms through which prebiotics may influence depression.

Main Methods:

• Systematic review of clinical trials involving various prebiotics.
• Analysis of dosages and effects of prebiotics like GOS, EGCG, and eicosapentaenoic acid.
• Examination of proposed biological mechanisms, including neurotransmitter synthesis and inflammation regulation.

Main Results:

• Galactooligosaccharides (GOS) at 5g/day and eicosapentaenoic acid (≤1g/day) effectively reduced depressive symptoms.
• Epigallocatechin gallate (EGCG) demonstrated potential antidepressant properties, possibly requiring 3g/day for significant impact.
• Key mechanisms involve neurotransmitter synthesis, short-chain fatty acid production, and inflammation modulation.

Conclusions:

• Specific prebiotics, notably GOS and eicosapentaenoic acid, offer viable therapeutic options for depression.
• Further research into optimal dosages and mechanisms of prebiotics like EGCG is warranted.
• Prebiotic interventions represent a promising avenue for managing depression through gut-brain axis modulation.